Readdressing the validity of Repeat Revascularization outcome in PCI vs CABG trials

Pablo Lamelas – In the last decades multiple trials comparing the efficacy of PCI vs CABG incorporated repeat revascularization in the primary composite outcome, which favoured CABG repeatedly, and frequently … Continue reading Readdressing the validity of Repeat Revascularization outcome in PCI vs CABG trials

NOACs in stable CAD with Atrial Fibrillation: with or without aspirin? The AFIRE trial

Fernando Botto – A general rule dictates “the more the antithombotic effect, the higher the risk of bleeding”. In stable CAD patients beyond 1 year of PCI or without prior … Continue reading NOACs in stable CAD with Atrial Fibrillation: with or without aspirin? The AFIRE trial

Ticagrelor vs Prasugrel ISAR-REACT 5: A lesson learned

Pablo Lamelas – One of the top surprises from ESC congress 2019 was ISAR-REACT 5 trial, which concluded that in acute coronary syndromes Prasugrel was superior to Ticagrelor for efficacy … Continue reading Ticagrelor vs Prasugrel ISAR-REACT 5: A lesson learned

Complete vs Culprit Only Revascularization after STEMI: Why do we need large trials like COMPLETE?

Pablo Lamelas – Multiple small randomized trials evaluating the effect of complete revascularization in STEMI suggested that complete revascularization was associated with a marked reduction (50%) in cardiovascular death, as … Continue reading Complete vs Culprit Only Revascularization after STEMI: Why do we need large trials like COMPLETE?

Oral anticoagulation in Atrial Fibrillation with CHA2DS2-VASc = 1: too much uncertainty?

Fernando Botto – Patients with any form of Atrial Fibrillation (AF) having an estimated thromboembolic risk (stroke or systemic embolism) of 1% or more per year should be considered for … Continue reading Oral anticoagulation in Atrial Fibrillation with CHA2DS2-VASc = 1: too much uncertainty?